Bladder Neoplasm, Carcinoma in Situ, Mycobacterium, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma
Conditions
Keywords
Urinary Bladder Neoplasms, Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Urinary Bladder Diseases, Urologic Diseases, Mycobacterial cell wall DNA complex, Intravesical drug administration
Brief summary
This is a phase 3 randomized, active-controlled, open-label, multicenter study that will be conducted in approximately 120 investigational sites worldwide. Subjects with either recurrent or refractory NMIBC (Ta high grade, T1 low or high grade, CIS) will be eligible for participation in this study. Refractory disease is defined as evidence of persistent high grade bladder cancer (Ta HG, T1, and/or CIS) at least 6 months from the start of a full induction course of BCG with or without maintenance/re-treatment at 3 months. Recurrent disease is defined as reappearance of disease after achieving a tumor-free status by 6 months following a full induction course of BCG with or without maintenance/re-treatment at 3 months. Subjects with recurrent disease must have recurred within 18 months following the last dose of BCG. Approximately 450 subjects will be randomized. The primary objective of this study is to evaluate the efficacy of intravesical EN3348 as compared with mitomycin C in the treatment of subjects with recurrent or refractory NMIBC. The secondary objective is to evaluate the safety of EN3348 as compared with mitomycin C in the treatment of subjects with BCG recurrent or refractory NMIBC. This study will consist of 4 phases: Screening, Induction, Maintenance and Follow-Up and will be conducted over 3 years.
Interventions
BIOLOGICALEN3348
Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
BIOLOGICALMitomycin C
Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
Sponsors
Bioniche Life Sciences Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Is 18 years of age and older at time of consent signing * Have either BCG recurrent or refractory NMIBC: * Refractory disease is defined as evidence of persistent high grade bladder cancer (Ta HG, T1 and/or CIS) at least 6 months from the start of a full induction course of BCG with or without maintenance/re-treatment at 3 months * Recurrent disease is defined as reappearance of disease after achieving a tumor-free status by 6 months following a full induction course of BCG with or without maintenance/re-treatment at 3 months. Subjects with recurrent disease must have recurred within 18 months following the last dose of BCG * A full induction course of BCG is defined as at least 5 out of 6 total expected instillations of BCG within a period of 2 months, regardless of dose strength * Have histologically confirmed NMIBC (according to 2004 WHO classification) within 8 weeks prior to randomization * High grade Ta papillary lesion(s) * High or low grade T1 papillary lesion(s)(biopsy sample must include evidence of muscularis propria) * CIS, with or without Ta or T1 papillary tumor(s) of any grade * Have had all visible papillary and resectable CIS lesion(s) removed by TURBT within 8 weeks prior to randomization * Available for the duration of the study including follow-up (approximately 36 months) * Have an Eastern Cooperative Oncology Group (ECOG) performance status grade of 2 or less * Have no evidence of urothelial carcinoma involving the upper urinary tract or the urethra (confirmed by extravesical work up, which may include radiological imaging and/or biopsy) within 6 months of randomization: * If previous work up occurred more than 6 months from randomization, extravesical work up must be repeated prior to randomization in order to determine eligibility * Subjects (male and female) of child-bearing potential (including female subjects who are post-menopausal for less than 1 year) must be willing to practice effective contraception (as defined by the Investigator) during the study and be willing and able to continue contraception for 30 days after their last dose of study treatment * Is able to understand and give written informed consent
Exclusion criteria
* Current or previous history of muscle invasive bladder tumors * Current or previous history of lymph node positive and/or metastatic bladder cancer * Current evidence of pure squamous cell carcinoma, pure adenocarcinoma or pure undifferentiated carcinoma of the bladder * Currently receiving systemic cancer therapy (cytotoxic/cytostatic or immunotherapy) * Currently receiving treatment with a prohibited therapy * Current or prior history of systemic lupus erythematosus * Systemic immunotherapy within 6 months of randomization * Treatment with an investigational agent within 30 days or 5 half lives from randomization, whichever is longer * Prior treatment with an intravesical chemotherapeutic agent within 3 months of randomization except for single perioperative dose of chemotherapy immediately post-TURBT * Prior treatment with EN3348 (MCC) or any other mycobacterial cell wall composition or formulation * Refractory to mitomycin C (failure to achieve tumor-free status following minimum of a 6 week induction course of mitomycin C) * Contraindication to mitomycin C * Untreated urinary tract or bladder infection * ANC \<1000/µL and hemoglobin \<10 g/dL * Known cardiovascular disease such as myocardial infarction within the past 3 months, unstable angina pectoris, congestive heart failure (NYHA Class III or IV) or uncontrolled cardiac arrhythmia * Female subjects who are pregnant or lactating * Congenital or acquired immune deficiency * Have current or history of documented or suspected malignancy of any organ system (diagnosed, treated or untreated) within the past 5 years (with the exception of localized transitional cell carcinoma of the ureter treated with ureterectomy or nephroureterectomy, adequately treated basal cell or squamous cell carcinoma of the skin or asymptomatic non-metastatic prostate cancer either previously successfully treated or currently under active surveillance or receiving hormone therapy only) * Bladder contracture or history of an inability to retain the instillate for a minimum of 1 hour, even with premedication * Inability to tolerate intravesical administration or intravesical surgical manipulation (cystoscopy or biopsy) * Clinically significant active infections * Any medical or psychiatric condition which, in the opinion of the investigator, would preclude the participant from adhering to the protocol or completing the trial per protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of Event-free Survival of Intravesical EN3348 With Mitomycin C. | 1 year | Primary efficacy endpoint will be event-free survival - the interval from randomization to an event. An event is defined as tumor recurrence, tumor progression to muscle invasive bladder cancer or death, whichever occurs first. Tumor recurrence or progression must be documented by bladder biopsy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of Safety of EN3348 With Mitomycin C [Adverse Events (Other Than Serious Adverse Events) With Frequency Threshold of 5% or Greater]. | Through study early termination, approximately 23 months from first subject enrolled. | Safety endpoint displayed includes adverse events (other than serious adverse events) with a frequency threshold of 5% or greater, for each treatment arm. No statistical comparisons have been performed between the 2 treatment arms. |
Countries
Canada, Germany, Netherlands, Poland, United Kingdom, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| EN3348 8 mg EN3348 mixed with water for injection for a total volume of 50mL
EN3348: Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12 | 39 |
| Mitomycin C 40 mg mitomycin C mixed with water for injection to a total volume of 40 mL
Mitomycin C: Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12 | 45 |
| Total | 84 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Randomized but not treated | 2 | 0 |
| Overall Study | Study terminated early | 35 | 41 |
Baseline characteristics
| Characteristic | EN3348 | Mitomycin C | Total |
|---|---|---|---|
| Age, Continuous | 73.0 years STANDARD_DEVIATION 7.99 | 70.7 years STANDARD_DEVIATION 11.18 | 71.8 years STANDARD_DEVIATION 9.84 |
| Sex: Female, Male Female | 5 Participants | 12 Participants | 17 Participants |
| Sex: Female, Male Male | 34 Participants | 33 Participants | 67 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 32 / 37 | 35 / 45 |
| serious Total, serious adverse events | 4 / 37 | 2 / 45 |
Outcome results
Primary
Comparison of Event-free Survival of Intravesical EN3348 With Mitomycin C.
Primary efficacy endpoint will be event-free survival - the interval from randomization to an event. An event is defined as tumor recurrence, tumor progression to muscle invasive bladder cancer or death, whichever occurs first. Tumor recurrence or progression must be documented by bladder biopsy.
Time frame: 1 year
Population: The study was discontinued early. The number of subjects randomized at time of closure represented 18.7% of the planned enrollment of 450 subjects. Thus, the planned analysis as stated in the protocol was not performed. Only 2 subjects (5.1%) in the EN3348 arm and 4 subjects (8.9%) in the mitomycin C arm completed all planned doses.
Secondary
Comparison of Safety of EN3348 With Mitomycin C [Adverse Events (Other Than Serious Adverse Events) With Frequency Threshold of 5% or Greater].
Safety endpoint displayed includes adverse events (other than serious adverse events) with a frequency threshold of 5% or greater, for each treatment arm. No statistical comparisons have been performed between the 2 treatment arms.
Time frame: Through study early termination, approximately 23 months from first subject enrolled.
Population: Relevant safety data are presented in the Adverse Events and Serious Adverse Events Modules. Any clinically significant findings pertaining to other secondary outcomes such as vital signs, physical exams and laboratory test results would appear in these Modules as well. No statistical comparisons have been performed between the 2 treatment arms.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| EN3348 | Comparison of Safety of EN3348 With Mitomycin C [Adverse Events (Other Than Serious Adverse Events) With Frequency Threshold of 5% or Greater]. | Fatigue | 6 participants |
| EN3348 | Comparison of Safety of EN3348 With Mitomycin C [Adverse Events (Other Than Serious Adverse Events) With Frequency Threshold of 5% or Greater]. | Hematuria | 7 participants |
| EN3348 | Comparison of Safety of EN3348 With Mitomycin C [Adverse Events (Other Than Serious Adverse Events) With Frequency Threshold of 5% or Greater]. | Diarrhea | 3 participants |
| EN3348 | Comparison of Safety of EN3348 With Mitomycin C [Adverse Events (Other Than Serious Adverse Events) With Frequency Threshold of 5% or Greater]. | Dysuria | 9 participants |
| EN3348 | Comparison of Safety of EN3348 With Mitomycin C [Adverse Events (Other Than Serious Adverse Events) With Frequency Threshold of 5% or Greater]. | Back pain | 2 participants |
| EN3348 | Comparison of Safety of EN3348 With Mitomycin C [Adverse Events (Other Than Serious Adverse Events) With Frequency Threshold of 5% or Greater]. | Pollakiuria | 6 participants |
| EN3348 | Comparison of Safety of EN3348 With Mitomycin C [Adverse Events (Other Than Serious Adverse Events) With Frequency Threshold of 5% or Greater]. | Nausea | 2 participants |
| EN3348 | Comparison of Safety of EN3348 With Mitomycin C [Adverse Events (Other Than Serious Adverse Events) With Frequency Threshold of 5% or Greater]. | Urinary tract infection | 5 participants |
| Mitomycin C | Comparison of Safety of EN3348 With Mitomycin C [Adverse Events (Other Than Serious Adverse Events) With Frequency Threshold of 5% or Greater]. | Nausea | 3 participants |
| Mitomycin C | Comparison of Safety of EN3348 With Mitomycin C [Adverse Events (Other Than Serious Adverse Events) With Frequency Threshold of 5% or Greater]. | Dysuria | 12 participants |
| Mitomycin C | Comparison of Safety of EN3348 With Mitomycin C [Adverse Events (Other Than Serious Adverse Events) With Frequency Threshold of 5% or Greater]. | Hematuria | 3 participants |
| Mitomycin C | Comparison of Safety of EN3348 With Mitomycin C [Adverse Events (Other Than Serious Adverse Events) With Frequency Threshold of 5% or Greater]. | Pollakiuria | 6 participants |
| Mitomycin C | Comparison of Safety of EN3348 With Mitomycin C [Adverse Events (Other Than Serious Adverse Events) With Frequency Threshold of 5% or Greater]. | Urinary tract infection | 5 participants |
| Mitomycin C | Comparison of Safety of EN3348 With Mitomycin C [Adverse Events (Other Than Serious Adverse Events) With Frequency Threshold of 5% or Greater]. | Diarrhea | 2 participants |
| Mitomycin C | Comparison of Safety of EN3348 With Mitomycin C [Adverse Events (Other Than Serious Adverse Events) With Frequency Threshold of 5% or Greater]. | Back pain | 4 participants |
| Mitomycin C | Comparison of Safety of EN3348 With Mitomycin C [Adverse Events (Other Than Serious Adverse Events) With Frequency Threshold of 5% or Greater]. | Fatigue | 3 participants |